Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;2(3):245-254.
doi: 10.4155/cli.12.8.

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond

James G Kublin  1 , Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath, Lawrence Corey
Affiliations

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond

James G Kublin et al. Clin Investig (Lond). 2012 Mar.

Abstract

The HIV Vaccine Trials Network (HVTN) is an international collaboration of scientists and educators facilitating the development of HIV/AIDS preventive vaccines. The HVTN conducts all phases of clinical trials, from evaluating experimental vaccines for safety and immunogenicity, to testing vaccine efficacy. Over the past decade, the HVTN has aimed to improve the process of designing, implementing and analyzing vaccine trials. Several major achievements include streamlining protocol development while maintaining input from diverse stakeholders, establishing a laboratory program with standardized assays and systems allowing for reliable immunogenicity assessments across trials, setting statistical standards for the field and actively engaging with site communities. These achievements have allowed the HVTN to conduct over 50 clinical trials and make numerous scientific contributions to the field.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Location of clinical trial sites that have worked with the HIV Vaccine Trials Network. Numbers in parentheses indicate number of sites.
Figure 2
Figure 2. Timeline of some of the strategic accomplishments achieved by the HIV Vaccine Trials Network in the design, conduct and evaluation of clinical vaccine trials globally
Color coding depicts accomplishments in the areas of protocol development, laboratory, statistics, science, community engagement and future directions.
See this image and copyright information in PMC

References

    1. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005;79(16):10108–10125. - PMC - PubMed
    1. Seaman MS, Janes H, Hawkins N, et al. Tiered categorization of a diverse panel of HIV-1 env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010;84(3):1439–1452. - PMC - PubMed
    1. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods. 2007;323(1):39–54. - PMC - PubMed
    1. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine. 2007;25(3):510–518. - PubMed
    1. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008;82(24):12449–12463. - PMC - PubMed